I agree with you entirely on the importance of the ODAC outcome to the macro-narrative. I was trying to thread the needle between cautioning about the short-term (+5 day) SP based on SR-aGVHD market, while also acknowledging the huge potential in the long term in other applications.
ODAC effectively endorsed the MOA for Remestemcel-L, and FDA approval would cement that endorsement. My understanding is that is a huge step for a novel therapy with multiple potential applications because an application for a label extension will not face the same degree of MOA-related scrutiny as the initial application for approval (i.e. positive outcomes from clinical trials are more quickly and efficiently translated into label extensions than approvals for novel therapies).
- Forums
- ASX - By Stock
- MSB
- MSB Trading 2020 - a new dawn
MSB Trading 2020 - a new dawn, page-548
-
- There are more pages in this discussion • 12,523 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.16 |
Change
-0.030(2.52%) |
Mkt cap ! $1.324B |
Open | High | Low | Value | Volume |
$1.18 | $1.22 | $1.15 | $4.349M | 3.687M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
34 | 31722 | $1.16 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.17 | 22263 | 11 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
34 | 29338 | 1.160 |
14 | 36696 | 1.155 |
16 | 134053 | 1.150 |
18 | 210462 | 1.145 |
10 | 209327 | 1.140 |
Price($) | Vol. | No. |
---|---|---|
1.165 | 19911 | 8 |
1.170 | 89942 | 13 |
1.175 | 71347 | 9 |
1.180 | 77071 | 11 |
1.185 | 13924 | 3 |
Last trade - 14.04pm 15/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online